VIRT-NATE DHA (ASCORBIC ACID, CHOLECALCIFEROL, .ALPHA.-TOCOPHEROL, D-, THIAMINE MONONITRATE, RIBOFLAVIN, PYRIDOXINE HYDROCHLORIDE, FOLIC ACID, CYANOCOBALAMIN, FERROUS FUMARATE, MAGNESIUM OXID

VIRT-NATE DHA (ASCORBIC ACID, CHOLECALCIFEROL, .ALPHA.-TOCOPHEROL, D-, THIAMINE MONONITRATE, RIBOFLAVIN, PYRIDOXINE HYDROCHLORIDE, FOLIC ACID, CYANOCOBALAMIN, FERROUS FUMARATE, MAGNESIUM OXID
PDF | XML

NDC 69543-370-30
Set ID e554e0db-5f15-46d4-be02-dba3ba845063
Category DIETARY SUPPLEMENT
Packager Virtus Pharmaceuticals
Generic Name
Product Class
Product Number
Application Number
  • STATEMENT OF IDENTITY

    Prenatal/Postnatal Prescription Dietary Supplement

    69543-370-30

    Rx

  • DESCRIPTION

    Virt-Nate DHA is an orally administered prenatal/postnatal prescription dietary supplement with DHA and should be administered under the supervision of a licensed medical practitioner.

  • DIRECTIONS FOR USE

    Before, during, and/or after pregnancy regardless of lactation status, one softgel daily or as directed by a licensed healthcare practitioner.

    Supplement Facts
    Serving Size: 1 Softgel
    Amount Per Serving% Daily Value for Pregnant & Lactating Women
    *
    Daily Value not established
    Vitamin C (as ascorbic acid)100 mg167%
    Vitamin D (Vitamin D3 as cholecalciferol)400 IU100%
    Vitamin E (as d-alpha tocopherol)30 IU100%
    Thiamin (as thiamine mononitrate)3 mg176%
    Riboflavin3 mg150%
    Vitamin B6 (as pyridoxine HCl)20 mg800%
    Folic Acid1 mg125%
    Vitamin B12 (as cyanocobalamin)15 mcg188%
    Iron (as ferrous fumarate)28 mg156%
    Magnesium (as magnesium oxide)30 mg7%
    Zinc (as zinc oxide)20 mg133%
    Copper (as cupric sulfate)1 mg50%
    Omega-3 Fatty Acids (DHA-EPA)200 mg*

    Other Ingredients: Gelatin, Glycerin, Soybean Oil, Beeswax, Purified Water, Soy Lecithin, Natural Creamy Orange Flavor, Annatto Powder, Titanium Dioxide, and Ethyl Vanillin. Contains Fish Oil and Soy.

    KEEP THIS OUT OF REACH OF CHILDREN

  • CONTRAINDICATIONS

    Virt-Nate DHA should not be used by patients with known history of hypersensitivity to any of its ingredients.

  • WARNINGS

    WARNING: Accidental overdose of iron-containing products is a leading cause of fatal poisoning in children under 6. KEEP THIS PRODUCT OUT OF REACH OF CHILDREN. In case of accidental overdose, call a doctor or poison control center immediately.
  • CAUTIONS

    High levels of folic acid may, especially in older adults, hide signs of Vitamin B-12 deficiency (such as pernicious anemia, a condition that can cause nerve damage).

    Concurrent use of folic acid has been associated with enhanced phenytoin metabolism, lowering the level of the AED in the blood and allowing breakthrough seizures to occur. Caution should be used when prescribing this product among patients who are receiving treatment with phenytoin or other anticonvulsants.

    Exercise caution with the concomitant use of folinic acid and trimethoprim-sulfamethoxazole for the acute treatment of Pneumocystis carinii pneumonia in patients with HIV infection as it is associated with increased rates of treatment failure and mortality in a placebo controlled study.

    The action of levodopa is antagonized by pyridoxine.

    Products containing iron should not be used during dimercaprol therapy. Dimercaprol can bind to iron and cause kidney damage.

    Avoid administering omega-3 fatty acids to patients with inherited or acquired predisposition toward bleeding, including patients taking anticoagulants. Exercise caution with these patients to ensure that the prescribed dosage of DHA does not exceed 1 gram (1000 mg) per day.

  • SIDE EFFECTS

    Allergic sensitization has been reported following oral administration of folic acid.

    Iron can cause mild gastrointestinal side effects, particularly when taken on an empty stomach.

  • DRUG INTERACTIONS

    Folic Acid

    Concurrent use of folic acid has been associated with enhanced phenytoin metabolism, lowering the level of the AED in the blood and allowing breakthrough seizures to occur.

    Folinic acid may enhance the toxicity of fluorouracil.

    High levels of folic acid may result in decreased serum levels of pyrimethamine.

    Concurrent administration of chloramphenicol and folinic acid in folate-deficient patients may result in antagonism of the hematopoietic response to folate.

    Antiepileptic drugs (including, but not limited to, phenytoin, carbamazepine, primidone, valproic acid, fosphenytoin, valproate, phenobarbital and lamotrigine) have been shown to impair folate absorption and increase the metabolism of circulating folate.

    Fluoxetine

    Fluoxetine exerts a noncompetitive inhibition of the 5-methyltetrahydrofolate active transport system in the intestine.

    Decreased folic acid levels have been reported to be associated with the administration of Cholestyramine, Colestipol, Cycloserine, Dihydrofolate Reductase Inhibitors (aminopterin, methotrexate, pyrimethamine, triamterene, and trimethoprim), L-dopa, colchicine, oral contraceptives, methylprednisolone, pancreatic extracts (pancreatin, pancrelipase), prolonged intravenous pentamidine, smoking and alcohol consumption, sulfasalazine, metformin, heme iron, isotretinoin, and after a 6-month course of therapy, warfarin can produce a significant impairment of folate status.

    Thiamin (Vitamin B1)

    Furosemide, a loop diuretic, can decrease thiamin levels.

    There have been case reports that fluorouracil may increase thiamin metabolism.

    Vitamin B6

    Vitamin B6 should not be given to patients receiving the drug levodopa because the action of levodopa is antagonized by Vitamin B6. However, Vitamin B6 may be used concurrently in patients receiving a preparation containing both carbidopa and levodopa.

    Isoniazid can produce a Vitamin B6 deficiency.

    Vitamin B12

    Antibiotics, cholestyramine, colchicine, colestipol, metformin, para-aminosalicylic acid, and potassium chloride may decrease the absorption of vitamin B12, and nitrous oxide can produce a functional vitamin B12 deficiency.

    Vitamin D3

    Some thiazide diuretics, such as hydrochlorothiazide, as well as antacids, bile acid sequestrants (such as cholestyramine), mineral oil, orlistat, olestra, cimetidine, and anticonvulsant medications may reduce the absorption or increase the catabolism of Vitamin D.

    Vitamin D supplementation should not be given with calcium to patients with hypercalcemia or conditions that may lead to hypercalcemia such as hyperparathyroidism or those who form calcium-containing kidney stones.

    Iron

    Iron supplements might reduce the amounts of levodopa available to the body and diminish its clinical effectiveness.

    Levothyroxine ingested simultaneously with iron can result in clinically significant reductions in levothyroxine efficacy.

    Proton pump inhibitors reduce the acidity of stomach contents and can reduce iron absorption.

    Zinc

    Zinc may decrease absorption of quinolone or tetracycline antibiotics.

    Cupric oxide

    Concomitant use of penicillamine and copper can cause decreased absorption of both substances.

    Omega-3 Fatty Acids

    Ingestion of more than 3 grams per day of omega-3 fatty acids (ALA, EPA, and DHA) may have potential antithrombotic effects, and may increase bleeding times.

    Avoid administering omega-3 fatty acids to patients with inherited or acquired predisposition toward bleeding, including patients taking anticoagulants. Exercise caution with these patients to ensure that the prescribed dosage of DHA does not exceed 1 gram (1000 mg) per day.

  • PREGNANT AND NURSING MOTHERS

    Virt-Nate DHA is a prescription folate dietary supplement formulated for use before, during and/or after pregnancy regardless of lactation status.

    KEEP THIS PRODUCT OUT OF REACH OF CHILDREN.

  • HEALTH CLAIM

    Adequate folate in healthful diets may reduce a woman's risk of having a child with a brain or spinal cord defect.

  • HOW SUPPLIED

    Virt-Nate DHA is supplied as annatto colored softgel, imprinted with "V370," dispensed in bottles of 30 softgels.

  • STORAGE

    Store at controlled room temperature 15° to 30°C (59° to 86°F).

    Protect from light and moisture. Dispense in a tight, light-resistant container.

    Call your licensed medical practitioner about side effects. You may report side effects by calling Virtus at 1-888-848-3593 or FDA at 1-800-FDA-1088.

    KEEP THIS AND ALL DRUGS OUT OF THE REACH OF CHILDREN

    Rx

    Manufactured for
    Virtus Pharmaceuticals, LLC
    Tampa, FL 33619
    1-888-848-3593

    Made in Canada
    Rev. 12/2015

  • PRINCIPAL DISPLAY PANEL - 30 Softgel Bottle Label

    VIRTUS
    PHARMACEUTICALS

    69543-370-30

    Virt-Nate DHA

    PRENATAL/POSTNATAL

    Prescription Dietary Supplement
    with DHA

    Rx
    30 Softgels

    Made in Canada

    Principal Display Panel - 30 Softgel Bottle Label
  • INGREDIENTS AND APPEARANCE
    VIRT-NATE DHA 
    ascorbic acid, cholecalciferol, .alpha.-tocopherol, d-, thiamine mononitrate, riboflavin, pyridoxine hydrochloride, folic acid, cyanocobalamin, ferrous fumarate, magnesium oxide, zinc oxide, cupric sulfate, and omega-3 fatty acids capsule
    Product Information
    Product TypeDIETARY SUPPLEMENTItem Code (Source)NHRIC:69543-370
    Route of AdministrationORAL
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    ASCORBIC ACID (UNII: PQ6CK8PD0R) (ASCORBIC ACID - UNII:PQ6CK8PD0R) ASCORBIC ACID100 mg
    CHOLECALCIFEROL (UNII: 1C6V77QF41) (CHOLECALCIFEROL - UNII:1C6V77QF41) CHOLECALCIFEROL400 [iU]
    .ALPHA.-TOCOPHEROL, D- (UNII: N9PR3490H9) (.ALPHA.-TOCOPHEROL, D- - UNII:N9PR3490H9) .ALPHA.-TOCOPHEROL, D-30 [iU]
    THIAMINE MONONITRATE (UNII: 8K0I04919X) (THIAMINE ION - UNII:4ABT0J945J) THIAMINE3 mg
    RIBOFLAVIN (UNII: TLM2976OFR) (RIBOFLAVIN - UNII:TLM2976OFR) RIBOFLAVIN3 mg
    PYRIDOXINE HYDROCHLORIDE (UNII: 68Y4CF58BV) (PYRIDOXINE - UNII:KV2JZ1BI6Z) PYRIDOXINE20 mg
    FOLIC ACID (UNII: 935E97BOY8) (FOLIC ACID - UNII:935E97BOY8) FOLIC ACID1 mg
    CYANOCOBALAMIN (UNII: P6YC3EG204) (CYANOCOBALAMIN - UNII:P6YC3EG204) CYANOCOBALAMIN15 ug
    FERROUS FUMARATE (UNII: R5L488RY0Q) (FERROUS CATION - UNII:GW89581OWR) FERROUS CATION28 mg
    MAGNESIUM OXIDE (UNII: 3A3U0GI71G) (MAGNESIUM CATION - UNII:T6V3LHY838) MAGNESIUM CATION30 mg
    ZINC OXIDE (UNII: SOI2LOH54Z) (ZINC CATION - UNII:13S1S8SF37) ZINC CATION20 mg
    CUPRIC SULFATE (UNII: LRX7AJ16DT) (CUPRIC CATION - UNII:8CBV67279L) CUPRIC CATION1 mg
    OMEGA-3 FATTY ACIDS (UNII: 71M78END5S) (OMEGA-3 FATTY ACIDS - UNII:71M78END5S) OMEGA-3 FATTY ACIDS200 mg
    Inactive Ingredients
    Ingredient NameStrength
    GELATIN (UNII: 2G86QN327L)  
    GLYCERIN (UNII: PDC6A3C0OX)  
    SOYBEAN OIL (UNII: 241ATL177A)  
    YELLOW WAX (UNII: 2ZA36H0S2V)  
    WATER (UNII: 059QF0KO0R)  
    LECITHIN, SOYBEAN (UNII: 1DI56QDM62)  
    TITANIUM DIOXIDE (UNII: 15FIX9V2JP)  
    ETHYL VANILLIN (UNII: YC9ST449YJ)  
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NHRIC:69543-370-3030 in 1 BOTTLE
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    DIETARY SUPPLEMENT01/12/2016
    Supplement Facts
    Serving Size : Serving per Container :
    Amount Per Serving% Daily Value
    color
    scoring1
    shape
    size (solid drugs)14 mm
    imprint
    Labeler - Virtus Pharmaceuticals (079659493)